Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 43 out of 100. How common it is

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

In 2021, the age-standardized prevalence of AD and other dementia in China was 1,194 per 100,000 (95% CI: 1018-1,383), and the mortality rate was 35 per 100,000 (95% CI: 9-93). The disease burden was significantly higher in females compared to males (prevalence: females 1,559 per 100,000 vs. males 846 per 100,000). Joinpoint analysis showed a significant increase in both prevalence and mortality rates after 2019 (male APC = 2.81%, female APC = 3.76%). Risk factor analysis highlighted obesity (AAPC = 9.87%) as the leading contributor to AD mortality in China, surpassing global averages. The BAPC model predicted that by 2040, the prevalence in females would increase to 1,180 per 100,000, while the mortality rate for males would stabilize at 17.6 per 100,000. Our results indicate a substantial increase in disease burden, underscoring the urgent need for strategic interventions and resource allocation to mitigate the future impact of dementia-related conditions in China. The disease burden of AD and related dementia in China continues to rise, necessitating enhanced early screening, optimized healthcare resource allocation, and targeted intervention strategies for high-risk female populations.

What this study adds

Evidence grade: Moderate

The disease burden of Alzheimer's disease and other dementias in China continues to rise, with significantly higher prevalence in females than males and a notable increase in prevalence and mortality after 2019. Reported effect size: 2.81%; 3.76%; 9.87%.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Hou, M., & Yang, L. (2025). Trends and forecasts of the prevalence and mortality of Alzheimer’s disease and other dementias in China. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2025.1616232

Vancouver

Hou M, Yang L. Trends and forecasts of the prevalence and mortality of Alzheimer’s disease and other dementias in China. Frontiers in Public Health. 2025. doi:10.3389/fpubh.2025.1616232. PMID: 40766032.

BibTeX

@article{hou2025-40766032,
  author  = {Hou, Mingxuan and Yang, Ling},
  title   = {{Trends and forecasts of the prevalence and mortality of Alzheimer’s disease and other dementias in China}},
  journal = {Frontiers in Public Health},
  year    = {2025},
  doi     = {10.3389/fpubh.2025.1616232},
  pmid    = {40766032},
  url     = {https://doi.org/10.3389/fpubh.2025.1616232}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

The disease burden of Alzheimer's disease and other dementias in China continues to rise, with significantly higher prevalence in females than males and a notable increase in prevalence and mortality after 2019. Obesity was highlighted as the leading contributor to Alzheimer's disease mortality in China, surpassing global averages.

Study details

How this study scored 43/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 2 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record 1 of 4; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 43 of 100.43 of 100 points earned57 not earned

Published in a peer-reviewed journal. Scored zero for study design, sample size, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Frontiers in Public Health)
Journal's citation record 2 / 4 Frontiers in Public Health: journal h-index 174 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 2 / 7 Cited 10 times (OpenAlex, 2026-10-10)
Citations per year 2 / 5 3.3 citations a year over 3 year(s) since 2025
Impact for its field and year 3 / 6 Cited 6.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Ling Yang: h-index 14 (OpenAlex, whole career)
Institution's track record 0 / 3 Tongji University: institution h-index 628 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 40766032)
Free to read 2 / 2 Free to read
Total 43 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in How common it is from nearby years

Also in How common it is

80 studies in the library are filed under How common it is with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The How common it is hub.

Similar studies

More on How common it is

See all studies in How common it is →